Detection and neutralisation of heparin by a fluorescent ruthenium compound

Thrombosis and Haemostasis

Volumn 102, Issue 5, 2009, Pages 859-864

  Szelke, Helga ^a   Harenberg, Job ^a   Krämer, Roland ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Fluorescence; Heparin; Heparin antagonists; Heparin assay; Ruthenium

Indexed keywords

HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; RUTHENIUM COMPLEX;

ANTICOAGULATION; BLOOD CLOTTING TIME; CONFERENCE PAPER; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; FLUORESCENCE; HUMAN; HUMAN TISSUE; MOLECULAR PROBE; PRIORITY JOURNAL;

ANTICOAGULANTS; BLOOD COAGULATION TESTS; CHROMOGENIC COMPOUNDS; DRUG DESIGN; DRUG MONITORING; FACTOR XA; FIBER OPTIC TECHNOLOGY; FLUORESCENT DYES; HEPARIN ANTAGONISTS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MOLECULAR STRUCTURE; OLIGOPEPTIDES; ORGANOMETALLIC COMPOUNDS; POINT-OF-CARE SYSTEMS; SENSITIVITY AND SPECIFICITY; SPECTROMETRY, FLUORESCENCE;

EID: 70449559226     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH09-03-0168     Document Type: Conference Paper

References (23)

1. Van Kerkhof J C, Bergveld P, Schasfoort R B M. The ISFET based heparin sensor with a monolayer of protamine as affinity ligand. Biosens Bioelectron 1995; 10: 269-282.
2. Despotis, G J, Gravlee G, Filos K, et al. Anticoagulation monitoring during cardiac surgery: A review of current and emerging techniques. Anesthesiology 1999; 91: 1122-1151. (Pubitemid 29466546)
3. Jelinek R, Kolusheva S. Carbohydrate Biosensors. Chem Rev 2004; 104: 5987-6015.
4. Wright Zhong Z L, Anslyn E V. A functional assay for heparin in serum using a designed synthetic receptor. Angew Chem Int Ed 2005; 44: 5679-5682 (Pubitemid 41312153)
5. Wang S, Chang Y-T. Discovery of heparin chemosensors through diversity oriented fluorescence library approach. Chem Commun 2008; 1173-1175. (Pubitemid 351328037)
6. Metz S and Horrow J C. Pharmacology & Physiology in Anesthetic Practice, ed. Stoelting R K, Lippincott J B. Co., Philadelphia, PA, 1994; 1-15.
7. Verrecchio A, Germann M W, Schick B P, et al. Design of peptides with high affinities for heparin and endothelial cell proteoglycans. J Biol Chem 2000; 275: 7701-7707. (Pubitemid 30159673)
8. Schick B P, Gradowski J F, San Antonio J D, et al. Novel design of peptides to reverse the anticoagulant activities of heparin and other glycosaminoglycans. Thromb Haemostas 2001; 85: 482-487.
9. Fromm J R, Hileman R E, Caldwell E E O, et al. Pattern and spacing of basic amino acids in heparin binding sites. Arch Biochem Biophys 199; 343: 92-100.
10. Potempa L A, Gewurz H. Influence of heparin on interactions between C-reactive protein and polycations. Mol Immunol, 1983; 20: 501-509.
11. Chang L-C, Liang J F, Lee H-F, et al. Low molecular weight protamine (LMWP) as nontoxic heparin/low molecular weight heparin antidote (II): in vitro evaluation of efficacy and toxicity. AAPS pharmSci 2001; 3: E18.
12. Choi S, Clements D J, Pophristic V, et al. The design and evaluation of heparin-binding foldamers. Angew Chem Int Ed 2005; 44: 6685-6689.
13. Wu H-f, Lundblad R L, Church F C. Neutralization of heparin activity by neutrophil lactoferrin. Blood 1995; 85: 421-428.
14. Fabian I, Aronson M, Polycations as possible substitutes for protamine in heparin neutralization. Thromb Res 1980; 17: 239-247. (Pubitemid 10181841)
15. van deWesterlo E M A, Smetsers T F C M, Dennissen M A B A, et al. Human single chain antibodies against heparin: selection, characterization, and effect on coagulation. Blood 2002; 99: 2427-2433.
16. Croether M A, Warkentin T E, Bleeding risk and the management of bleeding complications in patients undergoing anticoagulant therapy: focus on new anticoagulants. Blood 2008; 111: 4871-4879.
17. Mecca T, Consoli G M L, Geraci C et al. Polycationic calyx[8]arenes able to recognize and neutralize heparin. Org Biomol Chem 2006; 4: 3763-3768.
18. Rozenberg G I, Espada J, de Cidre L L, et al. Heparan sulfate, heparin, and heparinase activity detection on polyacrylamide gel electrophoresis using the fluorochrome tris(2,2′-bipyridine)ruthenium(II). Electrophoresis 2001; 22: 3-11.
19. Harenberg J, Giese C; Dempfle C E, et al. Monitoring of heparin and low molecular weight heparin with capillary and venous whole blood. Thromb Haemostas 1988; 60: 377-381. (Pubitemid 19023726)
20. Creutz C, Sutin N. Electron Transfer Reactions of Excited States: Direct Evidence for Reduction of the Charge Transfer Excited State of Tris(2,2′-bipyridine) ruthenium(II). J Am Chem Soc 1976; 98: 6384-6385.
21. Casu B. Structure and active domain of heparin. In: Chemistry and Biology of Heparin and Heparan Sulfate. Oxford, Elsevier; 2005; 1-28.
22. Mulloy B, Forster M J, Jones C, et al, NMR and molecular- modelling studies of the solution conformation of heparin. Biochem J 1993; 293: 849-858. (Pubitemid 23244575)
23. Conrad H E, Heparin-Binding Proteins. San Diego, Academic Press; 1998.